<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6690">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02089503</url>
  </required_header>
  <id_info>
    <org_study_id>ELOUAN HSJ 2014</org_study_id>
    <nct_id>NCT02089503</nct_id>
  </id_info>
  <brief_title>Monocentric Retrospective Observational Study on Patients With Macular Degeneration</brief_title>
  <acronym>ELOUAN</acronym>
  <official_title>Monocentric Retrospective Observational Study Describing the Visual Acuity of Patients With Exudative Age Related Macular Degeneration and Treated by Lucentis® Under Real Conditions of Care.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main Objective: The main objective of this retrospective observational study was to describe
      the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy
      Study) scale, for patients with exudative Age-Related Macular Degeneration (ARMD),  treated
      with Lucentis, under real conditions of care, in terms of mean change of the Best Corrected
      Visual Acuity (BCVA), measured at 24 months (± 4 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).</measure>
    <time_frame>measured at 24 months (± 4 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the mean change of the BCVA throughout the 24 months of follow-up (FU),</measure>
    <time_frame>24 months of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Exudative Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>induction phase + intravitreal inj.</arm_group_label>
    <description>Group of patients who received Lucentis ®  with induction phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal inj. without induction</arm_group_label>
    <description>Group of patients who received Lucentis ®  without induction phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal inj. + monthly  follow-up</arm_group_label>
    <description>group of patients who were monthly monitored (+/- 1 week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal inj. + follow-up :&gt; 1 month</arm_group_label>
    <description>group of patients with Follow up visits intervals&gt; 1 month (+/- 1 week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal inj +induction+ month. FU</arm_group_label>
    <description>Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>date Lucentis® 1st intravitreal Inj.</arm_group_label>
    <description>Group of patients selected in accordance with the date of Lucentis®  treatment start.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intravitreal injections of Lucentis</intervention_name>
    <description>intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use</description>
    <arm_group_label>induction phase + intravitreal inj.</arm_group_label>
    <arm_group_label>intravitreal inj. without induction</arm_group_label>
    <arm_group_label>intravitreal inj. + monthly  follow-up</arm_group_label>
    <arm_group_label>intravitreal inj. + follow-up :&gt; 1 month</arm_group_label>
    <arm_group_label>intravitreal inj +induction+ month. FU</arm_group_label>
    <arm_group_label>date Lucentis® 1st intravitreal Inj.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with exudative Age-Related Macular Degeneration (ARMD),  treated with Lucentis,
        under real conditions of care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with exudative-subfove ARMD, regardless the neovessel type or the initial
             visual acuity; 2 - Patients treated in the department with intra vitreous injection
             of Lucentis ® during the study period (08/2011 and 02/2013); 3 - If both eyes are
             eligible, both will be analyzed;

        Exclusion Criteria:

          1. - Patients who received, for the studied eye, a  treatment with a Vascular
             endothelial growth factor (VEGF) other than Lucentis ® in the three months preceding
             the start of the study. For those who received combination therapy, the nature of the
             treatment will be specified and taken into account in the subgroups for statistical
             analyzes;

          2. - Patients with high myopia or neovessel not related to exudative-ARMD;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maud RIGHINI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>HSJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic QUEGUINER, MD</last_name>
    <phone>+33491806793</phone>
    <email>fqueguiner@hopital-saint-joseph.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic QUEGUINER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frederic QUEGUINER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital St. Joseph, Marseille, France</investigator_affiliation>
    <investigator_full_name>QUEGUINER, MD</investigator_full_name>
    <investigator_title>Ophtalmologist</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
